SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VaxGen Inc.-The 1st AIDS Vaccine in Phase 3 HumanTrials
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Manfred Sondermann who wrote (104)7/20/1999 7:09:00 AM
From: Manfred Sondermann   of 250
 
In the prospectus I found a marketing statement for AIDSVAX:

>[...] a UNAIDS study, which predicts that, within a decade,
>the worldwide need for HIV vaccine will exceed 650 million doses
>annually.

With these numbers, let us do the same calculation as in #104
again: with an AIDSVAX dose price of perhaps $25 (like the Hepatitis B
vaccine), and the same assumptions as in #104, the result is:

VXGN might have net earnings of $2.23 billion each year, and the
stock might trade at $5200, with a P/E of 35.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News